Protalix shareholders approve director elections, executive compensation, stock plan increase, auditor ratification

Protalix BioTherapeutics, Inc.

Elected eight directors: each with >28.7M votes; broker non-votes 10.7M for each.
Advisory approval of executive compensation: 28.4M for, 6.7M against, 0.2M abstain.
Approved stock plan amendment increasing authorized shares from 17.5M to 21.0M shares (28.2M for, 7.0M against).
Ratified Kesselman & Kesselman (PwC) as independent auditor for FY2026: 42.96M for, 2.0M against, 1.0M abstain.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.